TD Asset Management Inc Increases Stock Position in Lantheus Holdings, Inc. $LNTH

TD Asset Management Inc raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 25.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 790,950 shares of the medical equipment provider’s stock after buying an additional 158,358 shares during the period. TD Asset Management Inc owned about 1.16% of Lantheus worth $40,568,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Assenagon Asset Management S.A. purchased a new stake in shares of Lantheus during the third quarter worth approximately $65,654,000. Polaris Capital Management LLC acquired a new position in Lantheus during the 3rd quarter worth approximately $32,687,000. Norges Bank purchased a new stake in shares of Lantheus in the 2nd quarter valued at approximately $32,631,000. Boston Partners lifted its position in shares of Lantheus by 30.5% during the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after purchasing an additional 134,781 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Lantheus by 1.7% during the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on LNTH. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Tuesday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Citizens Jmp raised their price target on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday. JonesTrading restated a “hold” rating on shares of Lantheus in a research report on Friday. Finally, Mizuho raised their price target on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $82.17.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Price Performance

LNTH stock opened at $74.91 on Friday. The firm has a market cap of $4.97 billion, a P/E ratio of 22.23 and a beta of -0.08. The stock has a 50-day simple moving average of $68.15 and a 200-day simple moving average of $60.14. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.37% and a net margin of 15.15%.The business had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the previous year, the company earned $1.59 earnings per share. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.